Krensavage Asset Management, LLC Kodiak Sciences Inc. Transaction History

Krensavage Asset Management, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	SELL	$1.8 - $7.49 $4,179 - $17,391	-2,322 Reduced 0.67%	342,312 $616,000
Q2 2023 Aug 11, 2023	SELL	$4.3 - $9.48 $493,876 - $1.09 Million	-114,855 Reduced 25.0%	344,634 $2.38 Million
Q1 2023 May 15, 2023	SELL	$4.81 - $8.88 $19,764 - $36,487	-4,109 Reduced 0.89%	459,489 $2.85 Million
Q4 2022 Feb 15, 2023	SELL	$6.52 - $8.05 $37,750 - $46,609	-5,790 Reduced 1.23%	463,598 $3.32 Million
Q3 2022 Nov 14, 2022	SELL	$7.57 - $12.5 $641,966 - $1.06 Million	-84,804 Reduced 15.3%	469,388 $3.63 Million
Q2 2022 Aug 16, 2022	BUY	$5.04 - $9.48 $522,103 - $982,052	103,592 Added 22.99%	554,192 $4.23 Million
Q1 2022 May 17, 2022	BUY	$7.09 - $89.45 $3.19 Million - $40.3 Million	450,600 New	450,600 $3.48 Million

39M

6.5K

5.8K

Ticker KOD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 52,040,200
Market Cap $417M
Description
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is KSI-301, an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as we...

Get notified when there are updates to the investment portfolio of Krensavage Asset Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Krensavage Asset Management, LLC with notifications on news.